» Articles » PMID: 17602225

Leukocyte Infiltration and Tumor Cell Plasticity Are Parameters of Aggressiveness in Primary Cutaneous Melanoma

Overview
Date 2007 Jul 3
PMID 17602225
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Various clinical and experimental observations detected an immunological host defense in cutaneous melanoma. In order to investigate the prognostic value of leukocyte effector mechanisms, we examined the presence of different subsets of leukocytes in tumor samples of 58 patients diagnosed with primary cutaneous melanoma. The presence of T lymphocytes, cytotoxic T lymphocytes, B lymphocytes, CD16+ cells and macrophages was correlated to Breslow depth. A significantly higher amount of several subsets of leukocytes was found in samples with a more progressed tumor stage and survival analysis demonstrated that a higher amount of T lymphocytes and CD16+ cells was associated with a short survival. The amount of FOXP3+ regulatory T lymphocytes did not correlate with survival, nevertheless, it correlated with the amount of total infiltrate. In contrast, analysis of the expression of CD69, a marker for activated lymphocytes, demonstrated that patients with a higher amount of CD69+ lymphocytes had a better survival. In addition, a new parameter for aggressiveness of melanoma, tumor cell plasticity [i.e., the presence of periodic acid Schiff's (PAS) reagent positive loops], also predicted short survival and a trend of a higher amount of tumor infiltrating leukocytes in tumors with PAS positive loops was observed. These findings demonstrate that leukocyte infiltration and the presence of PAS loops is a sign of tumor aggressiveness and may have prognostic value.

Citing Articles

Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Bida M, Miya T, Hull R, Dlamini Z Front Immunol. 2024; 15:1497522.

PMID: 39712007 PMC: 11659259. DOI: 10.3389/fimmu.2024.1497522.


Tissue adaptation of CD4 T lymphocytes in homeostasis and cancer.

Pereira M, Galvani R, Goncalves-Silva T, de Vasconcelo Z, Bonomo A Front Immunol. 2024; 15:1379376.

PMID: 38690280 PMC: 11058666. DOI: 10.3389/fimmu.2024.1379376.


Macrophage Response to Simulated Solar Radiation in the Development of Human Malignant Melanoma.

Chu S, Petukhova T, Bordeaux J, McCormick T, Cooper K Arch Clin Exp Dermatol. 2023; 3(1).

PMID: 37309359 PMC: 10259476. DOI: 10.46527/2583-6374.119.


A B-cell or a key player? The different roles of B-cells and antibodies in melanoma.

Rodgers C, Mustard C, McLean R, Hutchison S, Pritchard A Pigment Cell Melanoma Res. 2022; 35(3):303-319.

PMID: 35218154 PMC: 9314792. DOI: 10.1111/pcmr.13031.


Prognostic Landscape of Tumor-Infiltrating T and B Cells in Human Cancer.

Zheng M, Li Y, Liu Z, Zhang X, Zhou Y, Jiang J Front Immunol. 2022; 12:731329.

PMID: 35069521 PMC: 8771864. DOI: 10.3389/fimmu.2021.731329.


References
1.
Bates G, Fox S, Han C, Leek R, Garcia J, Harris A . Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34):5373-80. DOI: 10.1200/JCO.2006.05.9584. View

2.
Wanebo H, Cooper P, Hagar R . Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann Surg. 1985; 201(4):499-504. PMC: 1250740. DOI: 10.1097/00000658-198504000-00016. View

3.
Appay V, Jandus C, Voelter V, Reynard S, Coupland S, Rimoldi D . New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol. 2006; 177(3):1670-8. DOI: 10.4049/jimmunol.177.3.1670. View

4.
Martinez-Escribano J, Hernandez-Caselles T, Campillo J, Campos M, Frias J, Garcia-Alonso A . Changes in the number of CD80(+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients. Hum Immunol. 2003; 64(8):796-801. DOI: 10.1016/s0198-8859(03)00122-8. View

5.
Perricone M, Smith K, Claussen K, Plog M, Hempel D, Roberts B . Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother. 2004; 27(4):273-81. DOI: 10.1097/00002371-200407000-00003. View